Anhui Bonomic Biomedical Co., Ltd.

Main research purpose: Use minodronic acid tablets (trade name: Bonoteo, specification: 1mg/tablet) produced by Aisuo Biotech Co., Ltd. as the reference preparation, and use minodronic acid provided by Anhui Bonomeco Biopharmaceutical Co., Ltd. The tablet (specification: 1 mg/tablet) is the test preparation. A randomized, open-label, single-dose, four-cycle, fully repeated crossover design was adopted to compare the effects of minodronic acid after subjects took the test preparation and the reference preparation in the fasting state. The absorption rate and extent were evaluated to evaluate the bioequivalence of the two preparations in Chinese healthy subjects under fasting state. Secondary research purpose: To evaluate the safety of the test preparation minodronic acid tablets (specification: 1mg/tablet) and the reference preparation minodronic acid tablets (trade name: Bonoteo, specification: 1mg/tablet) orally administered to Chinese healthy subjects sex.

Main research purpose: Using bisoprolol amlodipine tablets (trade name: Kangxinan®, specifications: bisoprolol fumarate 5mg and amlodipine besylate (calculated as amlodipine) 5mg) produced by licensed manufacturer Merck Kft, Egis Pharmaceuticals PLC as reference preparation, and bisoprolol amlodipine tablets (specifications: bisoprolol fumarate 5mg and amlodipine besylate (calculated as amlodipine) 5mg) provided by Anhui Bonomeco Biopharmaceutical Co., Ltd. as test preparation, a randomized, open, single-dose, two-period double crossover design was used to evaluate the bioequivalence of the two preparations in fasting and fed states in healthy Chinese subjects. Secondary study objective: To evaluate the safety of the oral test preparation bisoprolol amlodipine tablets (specifications: bisoprolol fumarate 5 mg and amlodipine besylate (calculated as amlodipine) 5 mg) and the reference preparation (trade name: Kangxinan®, specifications: bisoprolol fumarate 5 mg and amlodipine besylate (calculated as amlodipine) 5 mg) in healthy Chinese subjects.

The main purpose of the study was to use rivaroxaban tablets (specification: 2.5 mg, trade name: Xarelto) produced by Bayer AG as the reference preparation and rivaroxaban tablets (specification: 2.5 mg) provided by Anhui Bonomei Biopharmaceutical Co., Ltd. as the test preparation. A randomized, open, single-dose, four-period, completely repeated crossover design was used to evaluate the bioequivalence of the two preparations in fasting and postprandial states in healthy Chinese subjects. Secondary purpose of the study was to observe the safety of oral administration of the test preparation rivaroxaban tablets (specification: 2.5 mg) and the reference preparation rivaroxaban tablets (specification: 2.5 mg, trade name: Xarelto) in healthy subjects.